VITROLIFE'S INTERIM REPORT, JANUARY - SEPTEMBER 2001
· Agreement signed with Millenium Biologixs Inc. in Ontario, Canada,
concerning the development and testing of Vitrolife´s proprietary
culture media for human tissue engineering, particularly cartilage and
· Acquisition of 10,7 % in Cell Therapeutics Scandinavia AB in
Göteborg, a company with core competence in stem cell-based
biotechnology and the development of embryonic stem cell lines.
· Successful launch of Perfadex® for lung transplantation in southern
· Business area Fertility Systems show strong growth in Asia.
· Biocompatible study for cross-linked hyaluronic acid successfully
· Production facility project in Denver, Colorado, USA runs according
· The operating result during the period amounted to -36,2 MSEK (-
16,8 MSEK) equivalent to an operating margin of -52,4 % (-27,6 %).
· Net sales amounted to 69,1 MSEK (61,0 MSEK) equivalent to an
increase of 13,2 % (39,4 %).
See attached interim report in Swedish with financial data in English.
Göteborg 24th of October 2001
Vitrolife AB (publ)
For further information, please contact:
Vitrolife: President and CEO Dr. Peter Svalander, tel +46-31-721 80 01
CFO Stefan Jacobsson, tel +46-31-721 80 10
Vitrolife's business mission is to develop, produce and sell advanced
products and systems for the preparation, cultivation, preservation and
support of cells, tissues and organs. Vitrolife intends to further
expand the Company's production capacity to meet an expected increase in
demand for its products, as well as strengthen its global market
position as a leading company in the development of innovative cell and
Vitrolife believes that the number of procedures performed annually
involving tissue and cell technologies will increase as new treatments
are introduced and existing treatments are improved. In addition,
Vitrolife expects that the regulation surrounding approval processes and
quality control for its products will increase. Vitrolife aims to create
competitive advantages from this regulation by meeting and exceeding
expected future demands of regulatory authorities, ahead of the
Since it commenced its operations in 1993, Vitrolife has expanded
rapidly. The Company currently has over 90 employees and sells its
products in over 80 countries. During the latest five-year period, sales
have increased by an average of 33 percent and totalled more than SEK 82
million for the fiscal year 2000.
The Vitrolife share is listed on the Stockholm Exchange
(Stockholmsbörsen) O-list under the ticker VITR.
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2001/10/24/20011024BIT00990/bit0001.pdf The full report in Swedish